Kisunla: the first drug shown to slow Alzheimer's decline gets FDA approval

Published · Researched 2026-09-22

What happened (dated facts)

On July 2, 2024, the U.S. FDA approved donanemab (marketed as Kisunla), an amyloid-targeting infusion, for adults with early symptomatic Alzheimer's disease — the second anti-amyloid drug to reach approval after lecanemab. In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed clinical decline by about 22% overall and by up to 35% in participants with less advanced disease, reducing the risk of disease progression (Clinical Dementia Rating scale) by roughly 37%. The drug carries a boxed warning for amyloid-related imaging abnormalities (ARIA), including brain swelling and microbleeds, so treatment requires monitoring with brain MRI.

Why it is genuinely positive

For the first time in the history of Alzheimer's medicine, a drug was shown in a large trial to meaningfully slow the disease itself rather than only treat symptoms — and regulators cleared it for patients. It is not a cure and it is not for everyone, but it turned a terminal, untreatable decline into something medicine can measurably bend.

Social pulse

On Threads (searched 2026-09-22), @askdrmia (a physician's podcast account) posted on September 22, 2026, summarizing frequently asked questions on new Alzheimer's treatments including donanemab (#askdrmiapodcast, #alzheimerstreatments, #donanemab) — evidence that the treatment is being discussed by medical professionals in public social channels, not just in press releases.

Verified quotes

None captured.

Verification

• Tier: 2
• Primary source: Psychiatric News alert summarizing the FDA approval, July 2024 (https://alert.psychnews.org/2024/07/fda-approves-donanemab-infusions-for.html?m=0). Proves: approval date, indication, trial effect sizes (22% / 35% / 37%), ARIA warning.
• Social sources: Threads — @askdrmia (Sept 22, 2026, physician podcast FAQ on new Alzheimer's treatments including donanemab). Proves: medical-professional public discussion of the treatment on social.
• Positivity check: approved disease-modifying therapy with measured slowing of decline — a genuine therapeutic advance, framed with the ARIA caveat.

Key facts

UNVERIFIED points

• Social-layer posts about donanemab were not yet observed; tier cannot be finalized until they are.
• Cost/pricing and real-world uptake figures were not verified and are not stated.

Sources

• Primary source: Psychiatric News alert summarizing the FDA approval, July 2024 ( — retrieval date not recorded